OPHT Ophthotech Corporation

1.38
+0.07  (+5%)
Previous Close 1.31
Open 1.32
Price To Book 10.62
Market Cap 56948006
Shares 41,266,671
Volume 261,587
Short Ratio
Av. Daily Volume 300,865

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 2020.
Zimura
Autosomal Recessive Stargardt Disease
Phase 2a initiation announced January 16, 2018 with data due 2H 2019.
Zimura
Idiopathic Polypoidal Choroidal Vasculopathy
Phase 2a top-line data released November 12, 2018 noted that treatment was generally well tolerated.
Zimura
Wet age-related macular degeneration (Wet-AMD)
Phase 3 data released December 12, 2016 - primary endpoint not met. Data from third trial released August 14, 2017- primary endpoint not met.
Fovista
Wet age-related macular degeneration (Wet-AMD)
Phase 2b initial data due 4Q 2019.
Zimura
Geographic atrophy

Latest News

  1. Ophthotech Corporation to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, February 26, 2019
  2. Recent Analysis Shows Amerco, McKesson, Ophthotech, IQVIA, Highwoods Properties, and ABM Industries Market Influences — Renewed Outlook, Key Drivers of Growth
  3. Ophthotech Corporation to Present at the 37th Annual J.P. Morgan Healthcare Conference
  4. Ophthotech Announces the Addition of Ophthalmic Industry Leader, Calvin (Cal) W. Roberts, M.D., to Its Board of Directors
  5. Ophthotech Announces the Addition of Ophthalmic Industry Leader, Adrienne L. Graves, Ph.D., Former Chief Executive Officer of Santen Inc., to Its Board of Directors
  6. How Many Ophthotech Corporation (NASDAQ:OPHT) Shares Do Institutions Own?
  7. Ophthotech (OPHT) Down 21.7% Since Last Earnings Report: Can It Rebound?
  8. Ophthotech Announces Results from Phase 2a Safety Trial of Zimura® in Combination with Lucentis® in Wet Age-Related Macular Degeneration
  9. Edited Transcript of OPHT earnings conference call or presentation 31-Oct-18 12:00pm GMT
  10. Ophthotech (OPHT) Q3 Earnings Beat, Gene Therapy in Focus
  11. Ophthotech: 3Q Earnings Snapshot
  12. Ophthotech Reports Third Quarter 2018 Financial and Operating Results
  13. Ophthotech Expands Gene Therapy Pipeline in Orphan Retinal Diseases with Exclusive Option for Novel Product Candidates to Treat Best Vitelliform Macular Dystrophy (Best Disease)
  14. Ophthotech Expands Innovative Retinal Disease Pipeline with Acquisition of Versant Ventures’ Inception 4
  15. Ophthotech Corporation to Report Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, October 31, 2018
  16. Ophthotech Completes Patient Recruitment As Planned for its Phase 2b Clinical Trial of Zimura® Monotherapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
  17. Ophthotech Corporation to Present at Chardan’s 2nd Annual Genetic Medicines Conference
  18. Is Ophthotech Corporation (NASDAQ:OPHT) Attractive At Its Current PE Ratio?